Strategies of sequential therapies in unresectable metastatic colorectal cancer: A meta-analysis

Current Oncology

Volumn 21, Issue 6, 2014, Pages 318-328

  Asmis, T ^a   Berry, S ^b   Cosby, R ^c   Chan, K ^b   Coburn, N ^b   Rother, M ^d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Peel Regional Cancer Program   (Canada)

Author keywords

Chemotherapy strategies; Meta analyses; Metastatic colorectal cancer; Palliative treatment; Systematic reviews

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

BIBLIOGRAPHIC DATABASE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL FEATURE; EVIDENCE BASED PRACTICE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT PLANNING;

EID: 84916202760     PISSN: 11980052     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.2146     Document Type: Review

References (24)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide [Web resource]. Ver. 2.0. Lyon, France: International Agency for Research on Cancer; 2010. [Current version available online at: http://globocan.iarc. fr; cited December 2, 2013]
2. Welch S, Spithoff K, Rumble RB, Maroun J on behalf of the Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:1152-62
3. Vickers M, Samson B, Colwell B, et al. Eastern Canadian colorectal cancer conference: setting the limits of resectable disease. Curr Oncol 2010;17:70-7
4. Van Cutsem E, Nordlinger B, Cervantes A on behalf of the esmo Guidelines Working Group. Advanced colorectal cancer: esmo clinical practice guidelines for treatment. Ann Oncol 2010;21(suppl 5):v92-7
5. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. [Erratum in: Stat Med 2004;23:1817]
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
7. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (cairo): a phase iii randomised controlled trial. Lancet 2007;370:135-42
8. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (mrc focus): a randomised controlled trial. Lancet 2007;370:143-52. [Erratum in: Lancet 2007;370:566]
9. Cunningham D, Sirohi B, Pluzanska A, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009;20:244-50
10. Ducreux M, Malka D, Mendiboure J, et al. on behalf of the Fédération Francophone de Cancérologie Digestive (ffcd) 2000-05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (ffcd 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12:1032-44
11. Seymour MT, Thompson LC, Wasan HS et al. on behalf of the focus2 Investigators and the National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (mrc focus2): an open-label, randomised factorial trial. Lancet 2011;377:1749-59
12. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
13. Giacchetti S, Perpoint B, Zidani R, et al. Phase iii multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47
14. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7. [Erratum in: Lancet 2000;355:1372]
15. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
16. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 2007;370:105-7
17. Colucci G, Gebbia V, Paoletti G, et al. Phase iii randomized trial of folfiri versus folfox4 in the treatment of advancer colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:4866-75
18. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the bicc-c study. J Clin Oncol 2007;25:4779-86
19. Souglakos J, Ziras N, Kakolyris S, et al. Randomised phase-ii trial of capiri (capecitabine, irinotecan) plus bevacizumab vs folfiri (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mcrc). Br J Cancer 2012;106:453-9
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
21. Kabbinavar FF, Schulz J, McCleod M, et al. A ddition o f bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase ii trial. J Clin Oncol 2005;23:3697-705
22. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 2010;28:4697-705
23. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
24. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase iii max study. J Clin Oncol 2010;28:3191-8.